PF-06737007 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a targeted inhibitor, specifically designed to interfere with certain signaling pathways that are crucial for cancer cell survival and proliferation. By blocking these pathways, it aims to halt the growth of tumors and induce apoptosis in cancer cells. This makes it a promising candidate for the treatment of various cancers, particularly those that are resistant to conventional therapies. Ongoing research focuses on evaluating its efficacy, safety, and optimal dosing in preclinical and clinical settings, with the goal of developing it into an effective anticancer drug.